Functional Constipation (FC)

4
Pipeline Programs
2
Companies
1
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%

On Market (2)

Approved therapies currently available

U
LINACLOTIDEApproved
linaclotide
Unknown Company
oral2023
AbbVie
LINZESSApproved
linaclotide
AbbVie
Guanylate Cyclase-C Agonist [EPC]oral2012

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
1
LinaclotidePhase 3Peptide1 trial
Active Trials
NCT05652205Completed123Est. Sep 2025
Ironwood Pharmaceuticals
1 program
1
LinaclotidePhase 3Peptide

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
AbbVieLinaclotide

Clinical Trials (1)

Total enrollment: 123 patients across 1 trials

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Start: Dec 2022Est. completion: Sep 2025123 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space